Initial management of Parkinson's disease

BMJ (Online)

Volumn 349, Issue , 2014, Pages

  Goetz, Christopher G ^a   Pal, Gian ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMANTADINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BEE VENOM; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOT DERIVATIVE; FLUVOXAMINE MALEATE; GLUTATHIONE; GM 608; GRANULOCYTE COLONY STIMULATING FACTOR; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; NEUROPROTECTIVE AGENT; NICOTINE PATCH; PAROXETINE; PIOGLITAZONE; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIPARKINSON AGENT;

AGITATION; AMYOTROPHIC LATERAL SCLEROSIS; AUTONOMIC DYSFUNCTION; BLURRED VISION; BRAIN DEPTH STIMULATION; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; CONSTIPATION; DAYTIME SOMNOLENCE; DEPRESSION; DIABETES MELLITUS; DIZZINESS; DOPAMINERGIC NERVE CELL; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG POTENCY; DRUG WITHDRAWAL; DYSKINESIA; EDEMA; EXERCISE; FATIGUE; FEVER; HALLUCINATION; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOTENSION; IMPULSE CONTROL DISORDER; INCIDENCE; INSOMNIA; LEG EDEMA; LEUKOPENIA; LIVEDO RETICULARIS; LOW DRUG DOSE; LUNG FIBROSIS; MELANOMA; MONOTHERAPY; MOTOR DYSFUNCTION; MULTIPLE CYCLE TREATMENT; MYOCLONUS; NAUSEA; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; ORTHOSTATIC HYPERTENSION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PREVALENCE; PSYCHOSIS; RECOMMENDED DRUG DOSE; RETROPERITONEAL FIBROSIS; REVIEW; SEDATION; SEROTONIN SYNDROME; SLEEP DISORDER; SUBTHALAMIC NUCLEUS; TACHYCARDIA; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VALVULAR HEART DISEASE; VISUAL HALLUCINATION; VOMITING; DISEASE COURSE; UNITED KINGDOM; UNITED STATES;

ANTIPARKINSON AGENTS; DISEASE PROGRESSION; GREAT BRITAIN; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; UNITED STATES;

EID: 84920829708     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g6258     Document Type: Review

References (131)

1. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384-6.
2. Obeso JA, Rodriguez-Oroz MC, Goetz CG, Goetz CG, Marin C, Kordower JH, et al. Missing pieces in the Parkinson's disease puzzle. Nat Med 2010;16:653-61.
3. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003;348:1356-64.
4. Benito-Leon J, Bermejo-Pareja F, Rodriguez J, Molina JA, Gabriel R, Morales JM, et al. Prevalence of PD and other types of parkinsonism in three elderly populations of central spain. Mov Disord 2003;18:267-74.
5. Morgante L, Rocca WA, Di Rosa AE, De Domenico P, Grigoletto F, Meneghini F, et al. Prevalence of Parkinson's disease and other types of parkinsonism: a door-to-door survey in three Sicilian municipalities. the Sicilian Neuro-Epidemiologic Study (SNES) group. Neurology 1992;42:1901-7.
6. De Rijk MC, Breteler MM, Graveland GA, Ott A, Grobbee DE, van der Meche FG, et al. Prevalence of Parkinson's disease in the elderly: the rotterdam study. Neurology 1995;45:2143-6.
7. De Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON collaborative study. European community concerted action on the epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:10-5.
8. Morgante L, Rocca WA, Di Rosa AE, De Domenico P, Grigoletto F, Meneghini F, et al. Prevalence of Parkinson's disease and other types of parkinsonism: a door-to-door survey in three Sicilian municipalities. The Sicilian neuro-epidemiologic study (SNES) group. Neurology 1992;42:1901-7.
9. De Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5:525-35.
10. Benito-Leon J, Bermejo-Pareja F, Morales-Gonzalez JM, Porta-Etessam J, Trincado R, Vega S, et al. Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain. Neurology 2004;62:734-41.
11. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999;52:1214-20.
12. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002;17(suppl 4):S1-166.
13. Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011;26(suppl 3):S2-41.
14. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54:93-101.
15. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361:1268-78.
16. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol 2002;59:1937-43.
17. Meister A, Anderson ME. Glutathione. Annu Rev Biochem 1983;52:711-60.
18. Reed DJ. Glutathione: toxicological implications. Annu Rev Pharmacol Toxicol 1990;30:603-31.
19. Ambani LM, Van Woert MH, Murphy S. Brain peroxidase and catalase in Parkinson disease. Arch Neurol 1975;32:114-8.
20. Jenner P. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand Suppl 1993;146:6-13.
21. Pearce RK, Owen A, Daniel S, Jenner P, Marsden CD. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J Neural Transm 1997;104:661-77.
22. Doo AR, Kim ST, Kim SN, Moon W, Yin CS, Chae Y, et al. Neuroprotective effects of bee venom pharmaceutical acupuncture in acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease. Neurol Res 2010;32(suppl 1):88-91.
23. Kim JI, Yang EJ, Lee MS, Kim YS, Huh Y, Cho IH, et al. Bee venom reduces neuroinflammation in the MPTP-induced model of parkinson's disease. Int J Neurosci 2011;121:209-17.
24. Salthun-Lassalle B, Hirsch EC, Wolfart J, Ruberg M, Michel PP. Rescue of mesencephalic dopaminergic neurons in culture by low-level stimulation of voltage-gated sodium channels. J Neurosci 2004;24:5922-30.
25. Tanner CM. Advances in environmental epidemiology. Mov Disord 2010;25(suppl 1):S58-62.
26. Fahn S, Isgreen WP. Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind crossover analyses. Neurology 1975;25:695-700.
27. Nicoletti A, Pugliese P, Nicoletti G, Arabia G, Annesi G, Mari MD, et al. Voluptuary habits and clinical subtypes of Parkinson's disease: the FRAGAMP case-control study. Mov Disord 2010;25:2387-94.
28. Quik M, Perez XA, Bordia T. Nicotine as a potential neuroprotective agent for Parkinson's disease. Mov Disord 2012;27:947-57.
29. Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC. Protective action of the peroxisome proliferator-activated receptorgamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 2002;82:615-24.
30. Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 2004;88:494-501.
31. Hunter RL, Dragicevic N, Seifert K, Choi DY, Liu M, Kim HC, et al. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J Neurochem 2007;100:1375-86.
32. Quinn LP, Crook B, Hows ME, Vidgeon-Hart M, Chapman H, Upton N, et al. The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B. Br J Pharmacol 2008;154:226-33.
33. Aviles-Olmos I, Limousin P, Lees A, Foltynie T. Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain 2013;136:374-84.
34. Frank T, Klinker F, Falkenburger BH, Laage R, Luhder F, Goricke B, et al. Pegylated granulocyte colony-stimulating factor conveys long-term neuroprotection and improves functional outcome in a model of Parkinson's disease. Brain 2012;135:1914-25.
35. Armitage JO. Emerging applications of recombinant human granulocytemacrophage colony-stimulating factor. Blood 1998;92:4491-508.
36. Schneider A, Kruger C, Steigleder T, Weber D, Pitzer C, Laage R, et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 2005;115:2083-98.
37. Meuer K, Pitzer C, Teismann P, Kruger C, Goricke B, Laage R, et al. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease. J Neurochem 2006;97:675-86.
38. Hartung T. Anti-inflammatory effects of granulocyte colony-stimulating factor. Curr Opin Hematol 1998;5:221-5.
39. Jung KH, Chu K, Lee ST, Kim SJ, Sinn DI, Kim SU, et al. Granulocyte colonystimulating factor stimulates neurogenesis via vascular endothelial growth factor with STAT activation. Brain Res 2006;1073-4; 190-201.
40. Gerecke KM, Jiao Y, Pani A, Pagala V, Smeyne RJ. Exercise protects against MPTP-induced neurotoxicity in mice. Brain Res 2010;1341:72-83.
41. Ahlskog JE. Does vigorous exercise have a neuroprotective effect in Parkinson disease? Neurology 2011;77:288-94.
42. Tajiri N, Yasuhara T, Shingo T, Kondo A, Yuan W, Kadota T, et al. Exercise exerts neuroprotective effects on Parkinson's disease model of rats. Brain Res 2010;1310:200-7.
43. Cohen AD, Tillerson JL, Smith AD, Schallert T, Zigmond MJ. Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF. J Neurochem 2003;85:299-305.
44. Chauhan NB, Siegel GJ, Lee JM. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain. J Chem Neuroanat 2001;21:277-88.
45. Mehrholz J, Friis R, Kugler J, Twork S, Storch A, Pohl M. Treadmill training for patients with Parkinson's disease. Cochrane Database Syst Rev 2010;1:CD007830.
46. Maesawa S, Kaneoke Y, Kajita Y, Usui N, Misawa N, Nakayama A, et al. Longterm stimulation of the subthalamic nucleus in hemiparkinsonian rats: neuroprotection of dopaminergic neurons. J Neurosurg 2004;100:679-87.
47. Nakao N, Nakai E, Nakai K, Itakura T. Ablation of the subthalamic nucleus supports the survival of nigral dopaminergic neurons after nigrostriatal lesions induced by the mitochondrial toxin 3-nitropropionic acid. Ann Neurol 1999;45:640-51.
48. Goetz CG, Wuu J, McDermott MP, Adler CH, Fahn S, Freed CR, et al. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord 2008;23:690-9.
49. Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ, et al. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2006;66:968-75.
50. Wilson RE, Seeberger LC, Silver D, Griffith A, Conner JB, Salzman PM, et al. Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment. Neurologist 2011;17:318-24.
51. Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011;26(suppl 3):S2-41.
52. Effect of deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med 1989;321:1364-71.
53. Allain H, Pollak P, Neukirch HC. Symptomatic effect of selegiline in de novo parkinsonian patients. The French Selegiline Multicenter Trial. Mov Disord 1993;8(suppl 1):S36-40.
54. Mally J, Kovacs AB, Stone TW. Delayed development of symptomatic improvement by (-)-deprenyl in Parkinson's disease. J Neurol Sci 1995;134:143-5.
55. Palhagen S, Heinonen EH, Hagglund J, Kaugesaar T, Kontants H, Maki-Ikola O, et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology 1998;51:520-5.
56. Stern MB, Marek KL, Friedman J, Hauser RA, LeWitt PA, Tarsy D, et al. Doubleblind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord 2004;19:916-23.
57. Macleod AD, Counsell CE, Ives N, Stowe R. Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database Syst Rev 2005;3:CD004898.
58. Olanow CW. Selegiline: current perspectives on issues related to neuroprotection and mortality. Neurology 1996;47(6 suppl 3):S210-6.
59. Romberg RW, Needleman SB, Snyder JJ, Greedan A. Methamphetamine and amphetamine derived from the metabolism of selegiline. J Forensic Sci 1995;40:1100-2.
60. Ministry of Health and Long-Term Care, Ontario. Committee to Evaluate Drugs. Recommendations and reasons: rasagiline. 2010. www.health. gov.on.ca/en/pro/programs/drugs/ced/pdf/azilec2.pdf.
61. Ferreira JJ, Neutel D, Mestre T, Coelho M, Rosa MM, Rascol O, et al. Skin cancer and Parkinson's disease. Mov Disord 2010;25:139-48.
62. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61:561-6.
63. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361:1268-78.
64. Fieschi C, Nardini M, Casacchia M, Tedone ME. Amantadine for Parkinson's disease. Lancet 1970;1:945-6.
65. Parkes JD, Baxter RC, Curzon G, Knill-Jones RP, Knott PJ, Marsden CD, et al. Treatment of Parkinson's disease with amantadine and levodopa. A oneyear study. Lancet 1971;1:1083-6.
66. Cox B, Danta G, Schnieden H, Yuill GM. Interactions of L-dopa and amantadine in patients with parkinsonism. J Neurol Neurosurg Psychiatry 1973;36:354-61.
67. Mawdsley C, Williams IR, Pullar IA, Davidson DL, Kinloch NE. Treatment of parkinsonism by amantadine and levodopa. Clin Pharmacol Ther 1972;13:575-83.
68. Parkes JD, Baxter RC, Marsden CD, Rees JE. Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1974;37:422-6.
69. Fahn S, Isgreen WP. Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind crossover analyses. Neurology 1975;25:695-700.
70. Butzer JF, Silver DE, Sahs AL. Amantadine in Parkinson's disease. A double-blind, placebo-controlled, crossover study with long-term followup. Neurology 1975;25:603-6.
71. Von Voigtlander PF, Moore KE. Dopamine: release from the brain in vivo by amantadine. Science 1971;174:408-10.
72. Ing TS, Daugirdas JT, Soung LS, Klawans HL, Mahurkar SD, Hayashi JA, et al. Toxic effects of amantadine in patients with renal failure. CMAJ 1979;120:695-8.
73. Parkers JD, Marsden CD, Price P. Amantadine-induced heart-failure. Lancet 1977;1:904.
74. Koller WC. Pharmacologic treatment of parkinsonian tremor. Arch Neurol 1986;43:126-7.
75. Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev 2003;2:CD003735.
76. Friedman Z, Neumann E. Benzhexol-induced blindness in Parkinson's disease. BMJ 1972;1:605.
77. Sadeh M, Braham J, Modan M. Effects of anticholinergic drugs on memory in parkinson's disease. Arch Neurol 1982;39:666-7.
78. Syndulko K, Gilden ER, Hansch EC, Potvin AR, Tourtellotte WW, Potvin JH. Decreased verbal memory associated with anticholinergic treatment in Parkinson's disease patients. Int J Neurosci 1981;14:61-6.
79. Lang AE. Treatment of Parkinson's disease with agents other than levodopa and dopamine agonists: controversies and new approaches. Can J Neurol Sci 1984;11(1 suppl):210-20.
80. Hughes RC, Polgar JG, Weightman D, Walton JN. Levodopa in parkinsonism: the effects of withdrawal of anticholinergic drugs. BMJ 1971;2:487-91.
81. Horrocks PM, Vicary DJ, Rees JE, Parkes JD, Marsden CD. Anticholinergic withdrawal and benzhexol treatment in Parkinson's disease. J Neurol Neurosurg Psychiatry 1973;36:936-41.
82. Goetz CG, Nausieda PA, Weiner WJ, Klawans HL. Practical guidelines for drug holidays in parkinsonian patients. Neurology 1981;31:641-2.
83. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002;17(suppl 4):S1-166.
84. Geminiani G, Fetoni V, Genitrini S, Giovannini P, Tamma F, Caraceni T. Cabergoline in Parkinson's disease complicated by motor fluctuations. Mov Disord 1996;11:495-500.
85. Kunkler RB, Osborn DE, Abbott RJ. Retroperitoneal fibrosis caused by treatment with pergolide in a patient with Parkinson's disease. Br J Urol 1998;82:147.
86. Ling LH, Ahlskog JE, Munger TM, Limper AH, Oh JK. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease. Mayo Clin Proc 1999;74:371-5.
87. Lund BC, Neiman RF, Perry PJ. Treatment of Parkinson's disease with ropinirole after pergolide-induced retroperitoneal fibrosis. Pharmacotherapy 1999;19:1437-438.
88. Shaunak S, Wilkins A, Pilling JB, Dick DJ. Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide. J Neurol Neurosurg Psychiatry 1999;66:79-81.
89. Rascol O, Dubois B, Caldas AC, Senn S, Del Signore S, Lees A, et al. Early piribedil monotherapy of Parkinson's disease: a planned seven-month report of the REGAIN study. Mov Disord 2006;21:2110-5.
90. Kieburtz K; Parkinson Study Group PramiBID Investigators. Twice-daily, low-dose pramipexole in early parkinson's disease: a randomized, placebo-controlled trial. Mov Disord 2011;26:37-44.
91. Hauser RA, Schapira AH, Rascol O, Barone P, Mizuno Y, Salin L, et al. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Mov Disord 2010;25:2542-9.
92. Singer C, Lamb J, Ellis A, Layton G; Sumanirole for Early Parkinson's Disease Study Group. A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease. Mov Disord 2007;22:476-82.
93. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH, et al. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007;22:2398-404.
94. Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L; Ease-PD Monotherapy Study Investigators. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, doubleblind, non-inferiority crossover study. Curr Med Res Opin 2008;24:2883-95.
95. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010;67:589-95.
96. Gallagher DA, O'Sullivan SS, Evans AH, Lees AJ, Schrag A. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord 2007;22:1757-63.
97. Biglan KM, Holloway RG Jr, McDermott MP, Richard IH; Parkinson Study Group CALM-PD Investigators. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology 2007;69:187-95.
98. Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ, et al. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev 2008;2:CD006564.
99. Birkmayer W, Hornykiewicz O. The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin Wochenschr 1961;73:787-8.
100. Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism-chronic treatment with L-dopa. N Engl J Med 1969;280:337-45.
101. Cedarbaum JM, Kutt H, Dhar AK, Watkins S, McDowell FH. Effect of supplemental carbidopa on bioavailability of L-dopa. Clin Neuropharmacol 1986;9:153-9.
102. Nelson MV, Berchou RC, Lewitt PA, Kareti D, Kesaree N, Schlick P, et al. Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after sinemet. Clin Neuropharmacol 1989;12:91-7.
103. Fahn S; Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 2005;252(suppl 4):IV37-42.
104. Rascol O, Brooks DJ, Brunt ER, Korczyn AD, Poewe WH, Stocchi F. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 study group. Mov Disord 1998;13:39-45.
105. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 2000;284:1931-8.
106. Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-53.
107. LeWitt PA. Extending the action of levodopa's effects. In: LeWitt PA, Oertel W, eds. Parkinson's disease: the treatment options. Martin Dunitz, 1999:141-58.
108. Yahr MD. Clinical aspects of abnormal movements induced by L-dopa. In: Barbeau A, McDowell FH, eds. L-dopa and parkinsonism. Davis Company, 1970:101-8.
109. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-58.
110. Rajput AH. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in parkinson's disease. Mov Disord 2014;29:429.
111. Rajput AH, Stern W, Laverty WH. Chronic low-dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy. Neurology 1984;34:991-6.
112. Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, et al. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord 2013;28:1064-71.
113. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA 2014;311:1670-83.
114. Muller B, Assmus J, Herlofson K, Larsen JP, Tysnes OB. Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson's disease. Parkinsonism Relat Disord 2013;19:1027-32.
115. Rektorova I, Rektor I, Bares M, Dostal V, Ehler E, Fanfrdlova Z, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol. 2003;10:399-406.
116. Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol. 2006;253:601-7.
117. Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:573-80.
118. Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012;78:1229-36.
119. Dobkin RD, Menza M, Allen LA, Gara MA, Mark MH, Tiu J, et al. Cognitivebehavioral therapy for depression in Parkinson's disease: a randomized, controlled trial. Am J Psychiatry 2011;168:1066-74.
120. International Parkinson and Movement Disorder Society. Evidence based medicine publications. www.movementdisorders.org/MDS/Resources/ Publications-Reviews/EBM-Reviews1.htm.
121. Medeiros CA, Carvalhedo de Bruin PF, Lopes LA, Magalhaes MC, de Lourdes Seabra M, de Bruin VM. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study. J Neurol 2007;254:459-64.
122. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54:403-14.
123. Schumacher JM, Ellias SA, Palmer EP, Kott HS, Dinsmore J, Dempsey PK, et al. Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology 2000;54:1042-50.
124. Kefalopoulou Z, Politis M, Piccini P, Mencacci N, Bhatia K, Jahanshahi M, et al. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol 2014;7:83-7.
125. Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet 2014;383:1138-46.
126. Marks WJ Jr, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adenoassociated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 2008;7:400-8.
127. Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009;73:1662-9.
128. Brundin P, Barker RA, Conn PJ, Dawson TM, Kieburtz K, Lees AJ, et al. Linked clinical trials-the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments. J Parkinsons Dis 2013;3:231-9.
129. Barbayo E, Ansorena E, Blanco-Prieto MJ. Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems. Maturitas 2013;76:272-8.
130. Poewe W, Mahlknecht P, Jankovic J. Emerging therapies for Parkinson's disease. Curr Opin Neurol 2012;25:448-59.
131. Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, et al. EFNS/MDS-ES recommendations for the diagnosis of Parkinson's disease. European Parkinson's Disease Association. 2013. www.epda.eu.com/en/ research-papers/2013/ejn/01-01-eurjneurol/.